Cyted
Cyted uses AI and biomarkers for early cancer detection to prevent disease and improve outcomes.
Cyted uses AI and biomarkers for early cancer detection to prevent disease and improve outcomes.
Cyted is a UK-based startup utilizing AI and biomarkers for early cancer detection to enhance patient outcomes and prevent disease. Founded in 2020, the company aims to transform cancer diagnosis by providing digital diagnostic infrastructure for early detection. By leveraging cutting-edge artificial intelligence and innovative biomarkers, Cyted seeks to improve the understanding of healthcare professionals and enhance patient treatment results.
The startup operates within the AI, Biotechnology, Health Care, and Medical Devices industries. Cyted's innovative approach focuses on revolutionizing diagnostic methodologies to contribute to a world where diseases are prevented rather than treated.
Its last investment was a Non Equity Assistance investment received on 29 May 2024, with MedTech Innovator as the investor.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Non Equity Assistance | Unknown | 1 |
|
29 May 2024 |
| Grant | £1.00M | 1 |
|
12 Dec 2023 |
| Series A | £13.40M | 2 |
|
17 May 2023 |
| Grant | £3.40M | 1 | NHS England | 01 Apr 2023 |
| Grant | £499.78K | 1 |
|
14 Apr 2022 |
No recent news or press coverage available for Cyted.
We care about your data, and we'd love to use cookies make your experience better.
